Trends in Mortality Associated with Colorectal Diseases in the US (1999–2020)

Overview

This study analyzes mortality trends from colorectal diseases in the USA from 1999 to 2020, revealing that colorectal cancer (CRC) remains the leading cause of death among colorectal pathologies, while benign colorectal conditions also contribute significantly to mortality. Notably, mortality from benign conditions has remained stable over the past two decades, contrasting with the decline in CRC mortality.

Background

Colorectal diseases encompass a range of conditions, including colorectal cancer (CRC) and benign disorders, both of which have significant public health implications. CRC is a leading cause of cancer-related mortality globally, prompting extensive research and clinical focus. In contrast, benign colorectal conditions have received less attention, despite their impact on mortality rates, highlighting the need for a comprehensive understanding of all colorectal pathologies.

Data Highlights

Key Findings

• Colorectal pathologies accounted for 2.7% of total deaths in the USA from 1999 to 2020.
• CRC deaths significantly outnumbered those from benign colorectal conditions (CDR 216.16 vs. 68.54, p < 0.001).
• Mortality from benign colorectal conditions was higher than from inflammatory bowel disease (CDR 68.54 vs. 3.76, p < 0.001).
• Leading causes of death among benign conditions included Clostridioides difficile enterocolitis and diverticular disease.
• CRC-related mortality showed a declining trend (AAPC = -1.44%, p < 0.05), while mortality from benign conditions and IBD remained stable.

Clinical Implications

Healthcare providers should recognize the significant mortality associated with benign colorectal conditions, which may be underappreciated compared to CRC. Continued surveillance and research into benign conditions are essential to inform public health strategies and improve patient outcomes.

Conclusion

The findings underscore the importance of addressing both malignant and benign colorectal conditions in public health initiatives, as both contribute to mortality in the population. Further research is warranted to enhance understanding and management of benign colorectal pathologies.

References

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. Forecasting Mortality Rates at 30 Days, 90 Days, and 1 Year Following Colorectal Cancer Surgery Through a Data-Driven Methodology
8. Colorectal Cancer Statistics, 2026 - PMC
9. FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer | FDA
10. Revised version global guidelines on diverticular disease of the colon: the Fiesole Consensus report | Gut